Machine signal
Active cluster sell — 3 distinct insiders, $1.1M, window ends Sep 8, 2026.
Figures computed from official regulatory filings — .
Analysttarget 22.43 USD (+76%) · consensus 4.63/5 · 7 buy · 1 hold · 0 sell
Ownershipinsiders 0.07% · institutions 93.15% · short 7.5% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Contineum Therapeutics, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
Market information source · Oct 5, 2026
SEC company identity · Oct 5, 2026
Open-market timeline · full history
34 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Stengone Carmine N. | Sell | $41.1K | SEC |
| Stengone Carmine N. | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Stengone Carmine N. | Exercise | $2.5K | SEC |
| Stengone Carmine N. | Exercise | $2.5K | SEC |
| Stengone Carmine N. | Sell | $40K | SEC |
| Stengone Carmine N. | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Lorrain Daniel S. | Exercise | $1K | SEC |
| Lorrain Daniel S. | Sell | $400 | SEC |
| Lorrain Daniel S. | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Lorrain Daniel S. | Sell | $16.2K | SEC |
| Lorrain Daniel S. | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Lorrain Daniel S. | Exercise | $25.3 | SEC |
| Stengone Carmine N. | Exercise | $2.5K | SEC |
| Stengone Carmine N. | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Stengone Carmine N. | Sell | $40K | SEC |
| Lorrain Daniel S. | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Lorrain Daniel S. | Sell | $40.6K | SEC |
| Lorrain Daniel S. | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Lorrain Daniel S. | Exercise | $29.1K | Unusual size | SEC |
| Lorrain Daniel S. | Sell | $462.3K | Unusual size | SEC |
| Lorrain Daniel S. | Sell | $91.7K | SEC |
| Lorrain Daniel S. | Exercise | $4.2K | SEC |
| Watkins Tim | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Stengone Carmine N. | Exercise | $7.6K | Unusual size | SEC |
| Stengone Carmine N. | Exercise | $3.2K | SEC |